177 related articles for article (PubMed ID: 37976323)
1. Association of biomarkers of enteric dysfunction, systemic inflammation, and growth hormone resistance with seroconversion to oral rotavirus vaccine: A lasso for inference approach.
Mwila-Kazimbaya K; Bosomprah S; Chilyabanyama ON; Chisenga CC; Chibuye M; Laban NM; Simuyandi M; Huffer B; Iturriza-Gomara M; Choy RKM; Chilengi R
PLoS One; 2023; 18(11):e0293101. PubMed ID: 37976323
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Micronutrient and Environmental Enteric Dysfunction Assessment Tool and evaluation of biomarker risk factors for growth faltering and vaccine failure in young Malian children.
Arndt MB; Cantera JL; Mercer LD; Kalnoky M; White HN; Bizilj G; Boyle DS; de Hostos EL; Choy RKM
PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008711. PubMed ID: 32997666
[TBL] [Abstract][Full Text] [Related]
3. Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants.
Ahmed S; Iqbal J; Sadiq K; Umrani F; Rizvi A; Kabir F; Jamil Z; Syed S; Ehsan L; Zulqarnain F; Sajid M; Hotwani A; Rahman N; Ma JZ; McNeal M; Ann Costa Clemens S; Talat Iqbal N; Moore SR; Ali A
Vaccine; 2022 May; 40(25):3444-3451. PubMed ID: 35534310
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of rotavirus vaccine (RotarixTM) in infants with environmental enteric dysfunction.
Mwape I; Bosomprah S; Mwaba J; Mwila-Kazimbaya K; Laban NM; Chisenga CC; Sijumbila G; Simuyandi M; Chilengi R
PLoS One; 2017; 12(12):e0187761. PubMed ID: 29281659
[TBL] [Abstract][Full Text] [Related]
6. Plasma VP8∗-Binding Antibodies in Rotavirus Infection and Oral Vaccination in Young Bangladeshi Children.
Lee B; Colgate ER; Carmolli M; Dickson DM; Gullickson S; Diehl SA; Ara R; Alam M; Kibria G; Abdul Kader M; Afreen S; Ferdous T; Haque R; Kirkpatrick BD
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):127-133. PubMed ID: 34904667
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684685
[TBL] [Abstract][Full Text] [Related]
8. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008521. PubMed ID: 30912133
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: a randomised, controlled, open-label, parallel, phase 4 trial.
Velasquez-Portocarrero DE; Wang X; Cortese MM; Snider CJ; Anand A; Costantini VP; Yunus M; Aziz AB; Haque W; Parashar U; Sisay Z; Soeters HM; Hyde TB; Jiang B; Zaman K
Lancet Infect Dis; 2022 Nov; 22(11):1606-1616. PubMed ID: 35961362
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
11. Association between Immunogenicity of a Monovalent Parenteral P2-VP8 Subunit Rotavirus Vaccine and Fecal Shedding of Rotavirus following Rotarix Challenge during a Randomized, Double-Blind, Placebo-Controlled Trial.
Fellows T; Page N; Fix A; Flores J; Cryz S; McNeal M; Iturriza-Gomara M; Groome MJ
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766217
[TBL] [Abstract][Full Text] [Related]
12. TLR genetic variation is associated with Rotavirus-specific IgA seroconversion in South African Black infants after two doses of Rotarix vaccine.
Miya TV; Groome MJ; de Assis Rosa D
Vaccine; 2021 Nov; 39(48):7028-7035. PubMed ID: 34740476
[TBL] [Abstract][Full Text] [Related]
13. Rotavirus-Specific Immunoglobulin A Responses Are Impaired and Serve as a Suboptimal Correlate of Protection Among Infants in Bangladesh.
Lee B; Carmolli M; Dickson DM; Colgate ER; Diehl SA; Uddin MI; Islam S; Hossain M; Rafique TA; Bhuiyan TR; Alam M; Nayak U; Mychaleckyj JC; McNeal MM; Petri WA; Qadri F; Haque R; Kirkpatrick BD
Clin Infect Dis; 2018 Jul; 67(2):186-192. PubMed ID: 29394355
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants.
Chilengi R; Mwila-Kazimbaya K; Chirwa M; Sukwa N; Chipeta C; Velu RM; Katanekwa N; Babji S; Kang G; McNeal MM; Meyer N; Gompana G; Hazra S; Tang Y; Flores J; Bhat N; Rathi N
Vaccine; 2021 Jun; 39(27):3633-3640. PubMed ID: 33992437
[TBL] [Abstract][Full Text] [Related]
15. Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh.
Naylor C; Lu M; Haque R; Mondal D; Buonomo E; Nayak U; Mychaleckyj JC; Kirkpatrick B; Colgate R; Carmolli M; Dickson D; van der Klis F; Weldon W; Steven Oberste M; ; Ma JZ; Petri WA
EBioMedicine; 2015 Nov; 2(11):1759-66. PubMed ID: 26870801
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
17. Enteric virome negatively affects seroconversion following oral rotavirus vaccination in a longitudinally sampled cohort of Ghanaian infants.
Kim AH; Armah G; Dennis F; Wang L; Rodgers R; Droit L; Baldridge MT; Handley SA; Harris VC
Cell Host Microbe; 2022 Jan; 30(1):110-123.e5. PubMed ID: 34932985
[TBL] [Abstract][Full Text] [Related]
18. Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries.
Baker JM; Tate JE; Leon J; Haber MJ; Lopman BA
PLoS Med; 2019 Dec; 16(12):e1003005. PubMed ID: 31887139
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.
Kanungo S; Chatterjee P; Bavdekar A; Murhekar M; Babji S; Garg R; Samanta S; Nandy RK; Kawade A; Boopathi K; Kanagasabai K; Kamal VK; Kumar VS; Gupta N; Dutta S
Lancet Infect Dis; 2022 Aug; 22(8):1191-1199. PubMed ID: 35588754
[TBL] [Abstract][Full Text] [Related]
20. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005.
Wood D;
Vaccine; 2005 Dec; 23(48-49):5478-87. PubMed ID: 16129525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
